The new patent entitled, ‘Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects,’ relates to step-wise increase of lomitapide doses for the treatment of hyperlipidemia or hypercholesterolemia, including severe hypercholesterolemia.
Aegerion Pharma CEO Marc Beer said this patent is an important addition to the Aegerion intellectual property portfolio as titrating the doses enables lomitapide to be used at maximum efficacy while maintaining the highest tolerability profile for the patient.
"It has the potential to extend patent protection on the use of lomitapide to August 2027," Beer said.